These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31880231)

  • 1. Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts.
    Kannarkat JT; Good CB; Kelly E; Parekh N
    J Manag Care Spec Pharm; 2020 Jan; 26(1):63-66. PubMed ID: 31880231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value-Based Pharmaceutical Contracts: Value for Whom?
    Kannarkat JT; Good CB; Parekh N
    Value Health; 2020 Feb; 23(2):154-156. PubMed ID: 32113619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using the Delphi method to identify meaningful and feasible outcomes for pharmaceutical value-based contracting.
    Swart ECS; Parekh N; Daw J; Manolis C; Good CB; Neilson LM
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1385-1389. PubMed ID: 33119437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Employer and Plan Sponsor Views on Pharmacy Reimbursement.
    Stull M; Gupton C
    J Manag Care Spec Pharm; 2020 Jun; 26(6):710-712. PubMed ID: 32463776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Current Status of Outcomes-Based Contracting for Manufacturers and Payers: An AMCP Membership Survey.
    Duhig AM; Saha S; Smith S; Kaufman S; Hughes J
    J Manag Care Spec Pharm; 2018 May; 24(5):410-415. PubMed ID: 29337604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMCP Partnership Forum: Advancing Value-Based Contracting.
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1096-1102. PubMed ID: 29083973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMCP Partnership Forum: What's Next for Specialty Medication Benefit Design and Reimbursement.
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1206-1213. PubMed ID: 32780612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does a One-Size-Fits-All Cost-Sharing Approach Incentivize Appropriate Medication Use? A Roundtable on the Fairness and Ethics Associated with Variable Cost Sharing.
    Graff JS; Shih C; Barker T; Dieguez G; Larson C; Sherman H; Dubois RW
    J Manag Care Spec Pharm; 2017 Jun; 23(6):621-627. PubMed ID: 28530519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy.
    Garrison LP; Neumann PJ; Willke RJ
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1185-1192. PubMed ID: 31663458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMCP Partnership Forum: Designing Benefits and Payment Models for Innovative High-Investment Medications.
    J Manag Care Spec Pharm; 2019 Feb; 25(2):156-162. PubMed ID: 30698091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support.
    Garrison LP; Zamora B; Li M; Towse A
    J Manag Care Spec Pharm; 2020 Apr; 26(4):400-406. PubMed ID: 32223599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers.
    Morgan SG; Thomson PA; Daw JR; Friesen MK
    Health Policy; 2013 Oct; 112(3):248-54. PubMed ID: 23809914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMCP Partnership Forum: Integrated Delivery Networks' Role in Pharmaceutical Value-Based Agreements.
    J Manag Care Spec Pharm; 2019 May; 25(5):526-531. PubMed ID: 31039067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMCP Guide to Pharmaceutical Payment Methods.
    AMCP Task Force on Drug Payment Methodologies
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl C):S1-39. PubMed ID: 17970611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory, Policy, and Operational Considerations for Outcomes-Based Risk-Sharing Agreements in the U.S. Market: Opportunities for Reform.
    Goodman C; Villarivera C; Gregor K; van Bavel J
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1174-1181. PubMed ID: 31535596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical policies: effects of financial incentives for prescribers.
    Rashidian A; Omidvari AH; Vali Y; Sturm H; Oxman AD
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006731. PubMed ID: 26239041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge of paying for cost-effective cures.
    Zettler PJ; Fuse Brown EC
    Am J Manag Care; 2017 Jan; 23(1):62-64. PubMed ID: 28141931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aligning managed care contracts, compensation plans, and incentive models.
    Nugent ME
    Healthc Financ Manage; 2011 Nov; 65(11):88-92, 94, 96. PubMed ID: 22128600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.